The development of microvascular complications in diabetes is a complex process in which endothelial dysfunction is important. Emerging evidence suggests that arginase is a key mediator of endothelial dysfunction in type 2 diabetes mellitus by reciprocally regulating nitric oxide bioavailability. The aim of this prospective intervention study was to test the hypothesis that arginase activity is increased and that arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes and microvascular dysfunction.
complications associated with diabetes (7) , and microvascular complications in type 2 diabetes mellitus have been linked to impaired endothelial function (8 -10) . Reduced bioavailability of nitric oxide (NO) is a key factor behind endothelial dysfunction and the progression of cardiovascular disease due to its importance in normal vascular homeostasis (11) . NO is produced from L-arginine by endothelial NO synthase (eNOS) with citrulline as a coproduct. Arginase has emerged as a key regulator of NO bioavailability and endothelial function by hydrolyzing L-arginine to ornithine and urea (12, 13) . Thus, increased arginase activity may reduce the production of NO and increase production of reactive oxygen species due to substrate deficiency for eNOS (14) . Interestingly, vascular arginase has been demonstrated to be up-regulated in both animal models and patients with type 2 diabetes (15) (16) (17) . Blockade of arginase improves resistance and conduit artery endothelial function in patients with type 2 diabetes via a NO synthase (NOS)-dependent action (16, 18) , supporting an important role of arginase in endothelial dysfunction in type 2 diabetes. Further data suggest that arginase is involved in microvascular dysfunction in rats with type 2 diabetes, identifying this enzyme as a potential target for the treatment of microvascular complications in type 2 diabetes (15) . However, the efficacy of arginase inhibition to improve microvascular function in patients with type 2 diabetes has not been investigated. In the present study, we therefore tested the hypothesis that inhibition of arginase improves microvascular function in patients with type 2 diabetes and microvascular complications.
Subjects and Methods

Subjects
Patients were recruited from the Department of Endocrinology and Diabetology and the Department of Cardiology, Karolinska University Hospital, in Stockholm in 2014 -2015. Twelve patients with type 2 diabetes and microvascular dysfunction and 12 healthy controls were included after giving their written informed consent. Subjects were classified as having type 2 diabetes if fasting plasma glucose exceeded 7.0 mmol/L on two different occasions, if plasma glucose exceeded 11.1 mmol/L 2 hours after oral administration of 75 g of glucose, or if they had a history of type 2 diabetes. Microvascular dysfunction was defined as urine albumin-creatinine ratio Ͼ 3.0 mg/mmol or the presence of retinopathy determined by retinal photography. Exclusion criteria were age Ͼ 80 years, myocardial infarction or unstable angina within the last 3 months, changed dose of any vasodilator drug during the preceding 6 weeks, ongoing treatment with warfarin, or concomitant disease that may have interfered with the possibility for the patients to comply with or complete the study protocol. The control subjects were matched for age, were free of medication, had no medical history of any cardiovascular disease, and had a normal oral glucose tolerance test. All subjects gave their oral and written consent to participate. The study was approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki.
Experimental protocol
Subjects arrived at the laboratory in the morning after overnight fasting. They were instructed not to take their morning medication and to refrain from caffeine-or nicotine-containing products before the experiment. Subjects on long-acting insulin were instructed to take 50% of their ordinary dose the evening before the investigation. After collection of basal blood samples, the subjects were given a standardized breakfast. All investigations were performed with the subject in the supine position in a dimly lit room with a temperature of 23°C. A catheter was introduced in the brachial artery of the nondominant arm (left in all subjects) after local anesthesia (2 mL of carbocain 10 mg/mL) for drug administration. Cutaneous microvascular flow was determined by laser-Doppler flowmetry (LDF; Periflux 5000; Perimed AB) connected to drug delivery chambers. Two different chambers (approximately 0.2 mL) were filled with acetylcholine (Ach; 20 mg/mL) and sodium nitroprusside (SNP; 20 mg/mL) for the determination of endothelium-dependent and endotheliumindependent microvascular dilatation, respectively (19, 20) . The chambers were placed 5 cm apart on the forearm and connected to a power source (Perilont Power Supply; Perimed AB) for drug delivery by iontophoresis. The attachment sites were cleaned with saline before placement. The probes were heated to 32°C. The coefficient of variation of the iontophoretic method is 19% (19) . During an intra-arterial infusion of saline (1 mL/min), baseline LDF was recorded for 3 minutes. Endothelium-dependent and -independent microvascular dilatation was determined by three stimulations of 0.08, 0.14, and 0.20 mA for 60 seconds each (equivalent to 4.8, 8.4, and 12 millicoulombs). The response to each stimulation was recorded for 15 minutes to ensure that the maximum responses to Ach and SNP were obtained before the next stimulation started. Thereafter, an intrabrachial artery infusion of the arginase inhibitor N -hydroxy-nor-Larginine (nor-NOHA; 0.1 mg/min) was started. The dose of nor-NOHA was based on a previous study (16) . After 120 minutes, endothelium-dependent and -independent dilatation was reevaluated. Data were continuously recorded on a laptop with optimized software (Perisoft, version 2.5.5).
Plasma analysis
Blood samples were drawn in EDTA tubes. Routine blood samples were analyzed at the Department of Clinical Chemistry, Karolinska University Hospital. Additional samples were centrifuged at 4°C and 2000 g for 15 minutes. The supernatant was stored frozen at Ϫ80°C. Amino acids arginine, ornithine, and citrulline reflecting arginase and NOS activities (see Supplemental Figure 1 ) were analyzed by liquid chromatography tandem mass spectrometry (21) . The maximum intra-assay coefficient of variation for the amino acid analysis was 5.4%.
Substances
Ach (Bausch & Lomb Nordic AB) and SNP (Hospira Inc.) were diluted in sterile saline to a concentration of 20 mg/mL. Nor-NOHA (Bachem) was dissolved in double-distilled water to a concentration of 10 mg/mL, sterile filtrated through a Millipore filter, tested for bacterial toxins and sterility, and stored frozen at Ϫ80°C. On the study day, nor-NOHA was diluted in sterile saline.
Calculations and statistical analysis
Data are presented as mean Ϯ standard deviation unless stated otherwise. Based on a previous interventional study of microvascular function of comparable design (22), we estimated that 12 individuals were sufficient to detect a significant improvement in endothelium-dependent dilatation. Data on LDF were exported as mean values during 30 seconds. The responses to Ach and SNP were calculated as the area under the curve of the increase from baseline flow during the first 14 minutes after electrical stimulation. All LDF data were analyzed off-line by a person blinded to the group identification. Amino acids are expressed in absolute concentrations and as ratios to reflect arginase and NOS activities. Changes in endothelium-dependent and -independent vasodilatation within and between the groups were analyzed with repeated measures two-way ANOVA, whereas differences concerning clinical characteristics and amino acid concentrations were analyzed with unpaired Student's t test.
Normal distribution of data was tested using D'Agostino-Pearson normality test. A P Ͻ .05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc).
Results
Subject characteristics
Patient characteristics are presented in Table 1 . The subjects with type 2 diabetes had significantly higher body mass index (BMI), fasting glucose, glycosylated hemoglobin (HbA1C), and C-reactive protein (CRP), but lower total, high-density lipoprotein, and low-density lipoprotein cholesterol compared to the control subjects. No subject was a current smoker. All subjects tolerated the study protocol well, and no adverse effects were observed.
Endothelium-dependent and -independent vasodilatation
Basal LDF did not differ between the study groups. Baseline endothelium-dependent microvascular dilatation was significantly impaired in the type 2 diabetes group compared to the control group (Figure 1) . Endothelium-dependent dilatation improved significantly in patients with type 2 diabetes after administration of nor-NOHA (Figure 2 ). By contrast, endothelium-dependent dilatation was not affected by nor-NOHA in control subjects (Figure 2) . Accordingly, endothelium-dependent microvascular dilatation was similar in patients with type 2 diabetes and controls after arginase blockade (Figure 3 ). Endotheliumindependent microvascular dilatation induced by SNP did not differ between the groups, and it did not change significantly (P ϭ .1) in response to the intervention in any of the study groups (Figure 4 ).
Amino acid analysis
Subjects with type 2 diabetes had significantly higher plasma levels of ornithine than controls ( Table 2 ). The ratios of the substrate (arginine) and products of arginase (ornithine) and NOS (citrulline) were calculated as a reflection of the relative activities of arginase and NOS. Subjects with type 2 diabetes had higher ratios of ornithine/ citrulline and ornithine/arginine than the control group (Table 2) , indicating increased arginase activity.
Discussion
The main results of this study are: 1) arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes; and 2) patients with type 2 diabetes and microvascular complications have increased ornithine/citrulline and ornithine/arginine ratios. These observations indicate up-regulation of arginase activity that has important functional implications for microvascular dysfunction in patients with type 2 diabetes.
Microvascular complications are common clinical problems in patients with type 2 diabetes for which specific therapeutic targets remain to be identified. Several lines of evidence suggest that endothelial dysfunction is a key underlying cause of microvascular complications in type 2 diabetes (8, 9, 23). Our present results showing a reduction of endothelium-dependent microvascular dilatation in patients with type 2 diabetes are in line with these observations. Despite the fact that endothelial dysfunction occurs early, there is no treatment that specifically targets the cause of it. Emerging evidence suggests that arginase is of central importance for the development of endothelial dysfunction in diabetes (12) . Arginase is up-regulated in experimental models of diabetes (15) and in arterioles from patients with diabetes (17) resulting in impaired NO bioavailability. Furthermore, we have previously shown that arginase inhibition improves skeletal muscle resistance artery endothelial function in patients with type 2 diabetes and coronary artery disease via a NOS-dependent mechanism (16) . Based on these observations, we hypothesized that arginase inhibition would improve microvascular function in patients with type 2 diabetes. Accordingly, administration of the arginase inhibitor nor-NOHA significantly improved endothelium-dependent microvascular dilatation, but did not affect endothelium-independent dilatation in the patient group. Arginase inhibition did not affect microvascular function in the control group, demonstrating a specific effect in the diabetes group, in which it was able to normalize endothelium-dependent microvascular dila- press.endocrine.org/journal/jcem 3955 tation to the level observed in the control group. This interesting observation suggests that arginase is a critical mediator of microvascular endothelial dysfunction in patients with type 2 diabetes. Thus, arginase may be a promising target for therapy in patients with type 2 diabetes and microvascular complications.
Arginase is believed to impair endothelial function through multiple mechanisms. Because arginase and NOS metabolize the same substrate, it is reasonable to believe that increased arginase activity in diabetes reduces the availability of arginine for NOS to produce NO (12, 24) . Accordingly, a previous study demonstrated that the improvement in endothelial function after arginase inhibition in patients with type 2 diabetes was blocked by NOS inhibition (16) , clearly demonstrating its dependence on NO production. An additional mechanism may be that NOS produces superoxide during substrate deficiency (25, 26) , a phenomenon referred to as eNOS uncoupling (14) , which further reduces NO bioavailability. Arginase inhibition may reduce superoxide formation in diabetes by reversing eNOS uncoupling (25) . In order to estimate the relative activities of arginase and NOS, the ratios between their amino acid products ornithine (arginase) and citrulline (NOS) and substrate (arginine) were calculated (as illustrated in Supplemental Figure 1 ). Ornithine levels were increased in patients with type 2 diabetes, resulting in increased ratios of ornithine/citrulline and ornithine/arginine, supporting the theory of increased arginase activity. One may expect citrulline levels to be reduced in the group of patients with diabetes as a result of impaired NOS activity. However, citrulline may also be formed from ornithine by ornithine carbamoyl transferase and converted to arginine by aminosuccinate synthase and aminosuccinate lyase (27) , which complicates the interpretation of citrulline plasma levels. The present data suggesting increased arginase activity are supported by previous observations in plasma (28) as well as in corpus cavernosum in patients with type 2 diabetes (29). Several mechanisms may explain increased arginase activity in diabetes, including elevated glucose, reactive oxygen species, and proinflammatory cytokines (24) . Our study is, to our knowledge, the first to link increased arginase activity to microvascular endothelial dysfunction in patients with type 2 diabetes.
Certain limitations need to be acknowledged. The study was performed on a limited sample size. Despite this, significant differences were detected in baseline endothelial function and in the efficacy of arginase inhibition between the groups. These promising results need to be confirmed in a larger randomized controlled study. The investigations were not blinded, but all evaluation was performed off-line by personnel blinded to group identification. There are differences in basal characteristics that might affect endothelial function. The diabetes group had lower low-density lipoproteins and higher CRP and BMI, all of which may affect baseline endothelial function and arginase activity (12, 25) . Furthermore, baseline medication that affects baseline endothelial function in the group of diabetes patients may have been a confounder in the study. However, it is of interest that arginase inhibition improved endothelial function despite ongoing medication including angiotensin-converting enzyme inhibitors, statins, metformin, and incretins that all improve endothelial function per se (30, 31) . This suggests that arginase inhibition exerts beneficial effects on microvascular function beyond these established medications.
In conclusion, the present study demonstrates that arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes and microvascular complications. Arginase inhibition may represent a future therapeutic strategy targeting microvascular endothelial dysfunction in patients with type 2 diabetes. 
